Clinical Trials Sponsored by C4 Innovations, LLC

Total 245 results

Massachusetts General Hospital
Patient-Centered Outcomes Research Institute; Harvard University; C4 Innovations...

Enrolling by invitation

Optimizing and Advancing SBIRT in Schools (OASIS)

Adolescent Substance Use | Adolescent Drinking | Risk Behavior, Health

United States
VG Innovations, LLC

Enrolling by invitation

Clinical Outcome and Fusion Results Using the SiJoin® Transfixing Sacroiliac Fusion Device

Pelvic Fracture | Sacroiliitis | Sacroiliac Joint Dysfunction | Iatrogenic Injury | Osteitis Condensans Ilii

United States
VG Innovations, LLC

Withdrawn

Clinical Outcome and Fusion Results Using the VerteLoc® Facet Fixation Device

Spinal Stenosis

United States
Clinical Innovations, LLC

Terminated

Evaluation of Maternal Feedback to Shorten Pushing Efforts During Labor

Prolonged Second Stage of Labor

United States
Clinical Innovations, LLC

Unknown

Efficacy Study of Rapid Immunoassay Diagnostic Test Utilizing PP12 and AFP, ROM Plus

PROM

United States
Galena Innovations, LLC

Not yet recruiting

Preventing Preterm Birth With a Negative Pressure Cervical Cup: a Feasibility Study

Preterm Birth | Cervical Insufficiency | Short Cervix | Cervical Incompetence | Soft Cervix

United States
SCRI Development Innovations, LLC

Withdrawn

iCORE: Collaborative Orthopedics Outcomes Registry (iCORE)

Arthroplasty, Replacement, Knee | Arthroplasty, Replacement, Hip

United States
SCRI Development Innovations, LLC

Withdrawn

Sarah Cannon Outcomes Registry

Oncology

United States
SCRI Development Innovations, LLC

Terminated

SCRI Tissue Testing Registry

Melanoma | Lymphoma | Multiple Myeloma | Myelodysplastic Syndrome

United States
SCRI Development Innovations, LLC

Terminated

A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia

Leukemia, Myeloid, Acute

United States
Deep Brain Innovations LLC

Terminated

Temporally Optimized Patterned Stimulation (TOPS®) Deep Brain Stimulation (DBS) for the Treatment of Parkinson's Disease (TOPS)

Parkinson Disease

United States
SCRI Development Innovations, LLC

Completed

Utilization of the OncoCEE™ Platform to Evaluate Selected Biomarker Alterations in CTCs Isolated From Patients With MBC

Metastatic Breast Cancer

United States
Nitric Oxide Innovations LLC

Terminated

The Evaluation of Nitric Oxide Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patient of African American and Hispanic Origin

COVID-19

United States
Morphotek
SCRI Development Innovations, LLC

Completed

Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC

Adenocarcinoma | Breast Cancer | Carcinoma, Non-Small-Cell Lung | Colorectal Cancer | Pancreatic Cancer

United States
SCRI Development Innovations, LLC
Celgene

Terminated

Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma

Transitional Cell Carcinoma | Bladder Cancer | Urothelial Carcinoma

United States
SCRI Development Innovations, LLC
Novartis

Completed

INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme

Renal Cell Carcinoma | Colorectal Cancer | Glioblastoma Multiforme | Gliosarcoma

United States
SCRI Development Innovations, LLC
Pfizer

Completed

Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer

Small Cell Lung Cancer

United States
Orthocare Innovations, LLC
FastEquation Inc.

Completed

Evaluating the Foot Touch Framework Model

Barefoot Running

United States
Medicure
SCRI Development Innovations, LLC

Completed

Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention (SAVI-PCI)

Myocardial Infarction | Unstable Angina | Acute Coronary Syndromes

United States
SCRI Development Innovations, LLC
Novartis

Completed

Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme

Glioblastoma Multiforme

United States
Medicure
SCRI Development Innovations, LLC

Withdrawn

Aggrastat Truncated Length Against Standard Therapies in Percutaneous Coronary Intervention (ATLAST-PCI)

Myocardial Infarction | Percutaneous Coronary Intervention | Unstable Angina | Acute Coronary Syndromes
SCRI Development Innovations, LLC
Novartis

Terminated

Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
SCRI Development Innovations, LLC
Novartis

Completed

Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumor

United States
SCRI Development Innovations, LLC
GlaxoSmithKline

Completed

Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
SCRI Development Innovations, LLC
Bayer

Completed

Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme

Glioblastoma Multiforme

United States
SCRI Development Innovations, LLC
Amgen

Completed

Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC

Non-Small-Cell Lung Cancer

United States
SCRI Development Innovations, LLC
Novartis

Completed

LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients

Breast Cancer

United States
SCRI Development Innovations, LLC
Novartis

Completed

Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer

Metastatic Breast Cancer

United States
SCRI Development Innovations, LLC
Bayer

Completed

Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer

Breast Cancer

United States
SCRI Development Innovations, LLC
GlaxoSmithKline

Completed

Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer

Carcinoma, Small Cell

United States
SCRI Development Innovations, LLC
GlaxoSmithKline

Completed

Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma

Ovary Cancer
SCRI Development Innovations, LLC
GlaxoSmithKline

Completed

Weekly Topotecan in the Second-Line Treatment of Small Cell Lung Cancer

Lung Cancer
SCRI Development Innovations, LLC
Acerta Pharma, LLC

Completed

Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
NasaClip
Emergency Medical Innovations, LLC

Recruiting

Nasal Compression Device Study for Epistaxis

Epistaxis Nosebleed

United States
SCRI Development Innovations, LLC
Amgen

Completed

Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers

Neuroendocrine Cancer

United States
SCRI Development Innovations, LLC
Celgene

Completed

Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer

Metastatic Breast Cancer

United States
SCRI Development Innovations, LLC
Bayer

Completed

Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States
SCRI Development Innovations, LLC
Novartis

Completed

LBH589 Treatment for Refractory Clear Cell Renal Carcinoma

Renal Cell Carcinoma

United States
SCRI Development Innovations, LLC
Sanofi

Completed

Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer

Breast Cancer

United States
SCRI Development Innovations, LLC
Pfizer

Completed

A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)

Colorectal Cancer

United States
SCRI Development Innovations, LLC
Novartis

Completed

Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib

Non Small Cell Lung Cancer

United States
SCRI Development Innovations, LLC
Novartis

Withdrawn

Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel

Advanced Prostate Cancer

United States
SCRI Development Innovations, LLC
Amgen

Completed

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Colorectal Cancer

United States
SCRI Development Innovations, LLC
Novartis

Completed

Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors

Malignant Solid Tumour

United States
SCRI Development Innovations, LLC
Bayer

Completed

Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer

Ovarian Cancer

United States
SCRI Development Innovations, LLC
Bayer

Completed

PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors

Refractory Solid Tumors

United States
SCRI Development Innovations, LLC
Novartis

Completed

Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

Metastatic Melanoma

United States
SCRI Development Innovations, LLC
Bayer

Completed

Community Oncology Setting Disease Outcomes of Sorafenib (Nexavar) Use in Advanced Renal Cell Carcinoma

Renal Cell Carcinoma

United States
SCRI Development Innovations, LLC
Novartis

Terminated

LBH589 and Gemcitabine in the Treatment of Solid Tumors

Solid Tumors

United States
SCRI Development Innovations, LLC
Novartis

Completed

Imatinib and PTK787/ZK222584 in Refractory and/or Advanced Solid Tumors

Solid Tumors | Refractory Malignancy

United States

Clinical Trials Sponsored by C4 Innovations, LLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations